Is it me or is Amgen's future not as bright as management says it is

Discussion in 'Amgen' started by anonymous, Sep 21, 2016 at 12:52 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    1. Repatha is not doing well and the outcomes better be phenomenal
    2. Kyprolis is not selling as expected and the reps are not getting paid
    3. Parsabiv - Can't get approved
    4. Romo data - disappointing
    5. Migraine data is decent but high placebo effect and multiple players with similar data
    6. Amgen won't launch biosimilar of Humira but it's own biologics of Neulasta and Neupogen are under fire and losing patent battles
    7. Enbrel losing share in derm and now rheum. Slightly offset by price increases.
    8. CTEP inhibitor - now on the shelf

    The only bright spot is Prolia and Xgeva growth but those are limited and will peak out soon.

    To me Amgen is going to do one these 3 things:

    1. More RIFs
    2. Merge with another big player and then RIF
    3. Go buy some big assets

    1 and 2 seem more likely since Amgen hasn't been aggressive with M&A and its track record from meaningful products from M&A is pretty poor
     

  2. anonymous

    anonymous Guest

    Spot on. Sad but true.
     
  3. anonymous

    anonymous Guest

    The ship sailed a long time ago with this company and all corporate sales jobs. They all suck. It will not get better. So, just lay back and enjoy the drilling.
     
  4. anonymous

    anonymous Guest

    Amgen straight up lies to investors. This place is a sinking ship.
     
  5. anonymous

    anonymous Guest

    Add to your list...

    9. 2017-2018 launches of Humira biosimilars (Novartis/Sandoz, Merck/Samsung, Boehringer Ingelhiem, Baxter/Momenta and others) taking out a third or more of Enbrel sales.
    10. Potential for Enbrel biosimilars in 2019 with Novartis/Sandoz, Coherus challenging the 2011 US patent extensions
    11. Sensipar (a small molecule pharmaceutical) going generic and losing 90% of sales within the first 9 months off patent
    12. Double digit annual price increases to "grow" established products are no-more given recent Valient and Mylan price moves and resulting public/political outcry
     
  6. anonymous

    anonymous Guest

    The party's over. Time to cash out and move on.